Gilead Sciences Inc
(BSP:GILD34)
R$
260.26
-0.46 (-0.18%)
Market Cap: 650.76 Bil
Enterprise Value: 769.98 Bil
PE Ratio: 109.37
PB Ratio: 6.11
GF Score: 71/100 Gilead Sciences Inc at Leerink Partners Global Biopharma Conference Transcript
Mar 12, 2024 / 02:00PM GMT
Release Date Price:
R$186.39
(-0.53%)
Daina Michelle Graybosch
Leerink Partners LLC, Research Division - Senior MD of Immuno-Oncology and Senior Research Analyst
Okay. Good morning, everyone. My name is Daina Graybosch. I am analyst here at Leerink Partners. My team and I cover immuno-oncology and broader. And we -- one of the companies we cover is Gilead, and we're really excited today to host Cindy Perettie from Kite.
Cindy Perettie
Gilead Sciences, Inc. - EVP of Kite
Thank you. It's nice to be here.
Questions & Answers
Daina Michelle Graybosch
Leerink Partners LLC, Research Division - Senior MD of Immuno-Oncology and Senior Research Analyst
And so we're going to jump right in, because it's a busy year and busy week for CAR T. And we're going to talk all elements. So actually, let's start with BCMA. So Kite has licensed Arcellx's BCMA CAR T called Anito-Cel. And I wonder if you could talk about of all the potentially differentiating product attributes for Anito-Cel, which do you think will be most impactful in commercialization?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot